Pediatric multiple sclerosisNews & Research
11 curated articles for Pediatric multiple sclerosis — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Neurology and therapy May 14, 2026
Pediatric Radiologically Isolated Syndrome (RIS): A Case with Active Disease 18 Years Later.
Radiologically isolated syndrome (RIS) is defined by incidental MRI findings suggestive of central nervous system (CNS) demyelination in asymptomatic individuals. While uncommon in adults, RIS is exceptionally rare in the pediatric population. Its management, particularly regarding the timing and po...
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
- Multiple sclerosis (Houndmills, Basingstoke, England) May 13, 2026
Correlates of long-term clinical outcomes in pediatric multiple sclerosis: A 12-year study.
Identifying long-term outcome substrates in pediatric multiple sclerosis (Ped-MS) can inform treatment selection. We investigated clinical/magnetic resonance imaging (MRI) correlates over a median 12.3-year follow-up. Fifty-two Ped-MS patients and 23 healthy controls underwent baseline 3.0 T ...
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
- Therapeutic advances in neurological disorders Apr 24, 2026
Natalizumab for pediatric multiple sclerosis: a systematic review and meta-analysis.
Pediatric-onset multiple sclerosis (POMS) is the onset of MS before the age of 18 and accounts for 3%-5% of all multiple sclerosis (MS) cases. Natalizumab (NTZ) is among the higher-efficacy disease-modifying treatments (HETs) in MS and is increasingly used for POMS. In this systematic review and met...
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
- Journal of child neurology Mar 25, 2026
Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry.
This study evaluated the efficacy of the multiple sclerosis disease-modifying therapies, intramuscular interferon beta-1a (Avonex) and subcutaneous peginterferon beta-1a (Plegridy), using data from the United States Network of Pediatric Multiple Sclerosis Centers. In this retrospective analysis, 154...
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
- JAMA neurology Mar 23, 2026
Chronic Active Lesions in Pediatric Multiple Sclerosis.
Chronic Active Lesions in Pediatric Multiple Sclerosis.
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
- JAMA neurology Mar 23, 2026
Chronic Active Lesions in Pediatric Multiple Sclerosis-Reply.
Chronic Active Lesions in Pediatric Multiple Sclerosis-Reply.
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
- Cureus Mar 11, 2026
Pediatric-Onset Multiple Sclerosis at Age 10 Following Nephrotic Syndrome: Early Recognition and Successful Treatment With Fingolimod.
Pediatric-onset multiple sclerosis before the age of 10 is rare and poses significant diagnostic challenges. We report a 10-year-old boy who developed multiple sclerosis five years after remission of nephrotic syndrome. He presented with progressive left eye visual loss and vertigo. Advanced magneti...
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
- Annals of neurology Mar 7, 2026
Real-World Effectiveness of Switching to Oral or Infusion Versus Injectable Disease-Modifying Therapy in Pediatric Multiple Sclerosis.
To assess real-world effectiveness of switching disease-modifying therapy (DMT) in pediatric multiple sclerosis (MS) and clinically isolated syndrome (CIS) initially treated with platform injectables on disease activity. Of 2615 pediatric-onset demyelinating disease patients at 12 clinics in the Uni...
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
- Neurology and therapy Mar 6, 2026
Reducing Early-Life Smoke Exposure as a Preventive Strategy for Pediatric Multiple Sclerosis: Results from the PEDIGREE Study.
Assessing the environmental impact on multiple sclerosis (MS) is complex because of long disease latency and potential recall bias, especially for perinatal exposures. This study aimed to investigate the association between parental smoking and the development of pediatric MS (PedMS). As part of the...
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
- Children (Basel, Switzerland) Feb 27, 2026
Prevalence, Incidence, and Risk of Different Comorbidity Categories in Pediatric Multiple Sclerosis: A Systematic Review and Meta-Analysis Protocol.
Pediatric-onset multiple sclerosis (POMS), defined as onset before age 18, is increasingly recognized as a distinct entity, often associated with a more burdensome disease course and earlier disability milestones than adult-onset MS. Although comorbidities may significantly affect disease progressio...
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
- Neurology and therapy Feb 27, 2026
The Use of Patient-Reported Outcome Measures in Developmental Age: A Complementary Tool for Pediatric Multiple Sclerosis Prognosis.
In pediatric multiple sclerosis (MS), assessment of disease burden predominantly relies on outcome measures developed and validated in adult populations. The application of these tools to children and adolescents may compromise sensitivity and specificity, potentially resulting in an underestimation...
Why it matters: Recent peer-reviewed research on Pediatric multiple sclerosis that may be relevant for patients and caregivers.
More on Pediatric multiple sclerosis
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.